Lipid metabolism, inflammation |
DUR-928 (sulfated oxysterol) |
DUR-928 dose-escalation |
DUR-928 in patients with AH/ NCT03917407
|
Lipid metabolism, inflammation |
5-lipoxygenase inhibitor (DS102) |
DS102 versus placebo |
Efficacy and safety of orally administered DS102 in patients with acute AH/ NCT03452540
|
Inflammation, IL-1 |
IL-1 monoclonal antibody (canakinumab) |
Canakinumab versus placebo |
IL-1 signal inhibition in AH/ NCT03775109
|
Neutrophils, Hepatic regeneration |
Anakinra (plus zinc) and G-CSF (also known as filgrastim) |
Anakinra (plus zinc) versus prednisone or placebo; G-CSF versus prednisone or placebo |
Trial of anakinra (plus zinc), G-CSF, or prednisone in patients with SAH/ NCT04072822
|
G-CSF |
G-CSF versus steroid or placebo |
Efficacy and safety of G-CSF in patients with SAH with null or partial response to steroid/ NCT02442180
|
G-CSF |
G-CSF + standard medical therapy versus standard medical therapy |
GCSF in AH/ NCT03703674
|
Pegfilgrastim (pegylated form of filgrastim) |
Pegfilgrastim + standard of care versus standard of care |
Pegfilgrastim in patients with AH/ NCT02776059
|
Hepatic regeneration |
IL-22 (F-652) |
F-652 dose escalation |
Use of F-652 in patients with AH/ NCT02655510
|
Gut microbiota |
Probiotics |
Probiotic Lactobacillus rhamnosus GG versus placebo |
Novel therapies in moderately severe acute AH/ NCT01922895
|
Immunomodulation, Gut permeability |
Bovine colostrum (IMM-124E) |
IMM-124E versus placebo |
Comparison of bovine colostrum versus placebo in treatment of SAH: A randomized double-blind controlled trial/ NCT02473341
|
Oxidative stress, Infection |
Antioxidant (N-acetylcysteine, NAC) |
NAC + prednisolone versus prednisolone |
N-acetylcysteine to reduce infection and mortality for AH/ NCT03069300
|